

Niagen.

BIOSCIENCE

State of the Science

Clinical Research on Niagen®



Niagen Bioscience Scientific Advisory Board




Dr. Roger Kornberg

Ph.D.

Professor of Structural Biology, Stanford University School of Medicine

Nobel Prize Winner, Chemistry



Dr. Rudolph Tanzi

Ph.D.

Kennedy Professor of Neurology, Harvard University

Director, Genetics and Aging Research Unit, Massachusetts General Hospital



Dr. Charles Brenner

Ph.D.

Chair of the Department of Diabetes and Cancer Metabolism, City of Hope

World's foremost authority on NAD+



Dr. Bruce German

Ph.D.

Distinguished Professor Emeritus of Food, Nutrition, and Health, University of California, Davis

Leader in food, nutrition, and wellness innovation



Dr. Brunie H. Felding

Ph.D.

Associate Professor of Molecular Medicine, Scripps Research Institute

Renowned breast cancer researcher focused on NAD+ supplementation



Dr. Vilhelm (Will) Bohr

M.D., Ph.D., D.Sc.

Professor (AFL), Molecular Aging, University of Copenhagen

One of the world's most published researchers on aging and neurodegenerative disease




Dr. Pinchas Hassy Cohen

M.D.

USC School of Gerontology Dean

A recognized aging expert with pioneering research and discoveries on mitochondria and novel microproteins



2 years

is the longest duration of supplementation

Presterud et al., 2023

140 participants

is the largest population studied in a clinical trial


Conze et al., 2019

3000 mg

is the highest dose with established safety

Berven et al., 2023

1000 mg is the most extensively researched daily dose.



90% of the 41 Niagen® published, peer-reviewed, clinical studies were conducted independently

- 37 studies were conducted independently
- 4 studies were funded by Niagen Bioscience



Health Categories

Aging

Immune Health

Muscle Health

Cardiovascular Health

Liver Health

Neurological Health

Gut Health

Pharmacokinetic/
Safety

Metabolic Health

Table 1. All peer-reviewed, published clinical studies on Niagen®

[†]Indicates an increase in blood or tissue NAD+ levels and/or NAD+ flux (the rate at which cells make and use NAD+) was observed.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Wu et al., 2025[†] Effects of Nicotinamide Riboside on NAD+ Levels, Cognition, and Symptom Recovery in Long-COVID: A Randomized Controlled Trial	2000 mg	20 weeks	Neurological Health Metabolic Health	Randomized, double-blind, placebo-controlled study in 58 non-hospitalized individuals with long COVID	- Niagen NR significantly boosted NAD+ levels by up to 210% after 5 weeks of supplementation and remained significantly elevated by 110% by the end of the 20-week intervention. - While primary outcomes were not significant between Niagen NR and placebo, participants taking Niagen NR showed significant improvements from baseline to week 10 in executive functioning, fatigue severity, sleep quality, and symptoms of depression. - The placebo plus exercise group (PL+Ex) trended toward a greater reduction in daytime systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to Niagen NR alone. Notably, the Niagen NR plus exercise group (NR+Ex) trended toward an increase in daytime SBP and DBP.
Lin et al., 2025 Nicotinamide Riboside Combined With Exercise To Treat Hypertension In Middle-Aged And Older Adults: A Pilot Randomized Clinical Trial	1000 mg	6 weeks	Cardiovascular Health	Randomized, double-blind, placebo-controlled pilot study in 54 sedentary older adults with hypertension	- NR+Ex also trended toward a greater reduction in arterial stiffness compared to PL+Ex, as measured by a decrease in pulse wave velocity (PWV). In contrast, the Niagen NR only group showed a trend toward an increase in PWV. - Among participants not taking antihypertensive medications, both NR+Ex and PL+Ex groups trended toward reductions in daytime SBP. For nighttime SBP, both groups also trended toward reductions, with larger reductions observed in NR+Ex. Daytime DBP trended downward in both NR+Ex and PL+Ex, while nighttime DBP decreased across all groups, with the largest reduction seen in NR+Ex.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Shoji et al., 2025[†] Nicotinamide Riboside Supplementation Benefits in Patients with Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial	1000 mg	26 weeks	 Aging	Randomized, double-blind, placebo-controlled, crossover study in 9 patient with Werner Syndrome	- Niagen NR improved arterial stiffness, as measured by the cardio-ankle vascular index (CAVI). - Niagen NR increased the number of high-density lipoprotein (HDL) particles. - Niagen NR reduced skin ulcer size and tended to prevent heel pad thinning, while ulcers worsened in the placebo group.
Ahmadi et al., 2025 A Pilot Trial of Nicotinamide Riboside and Coenzyme Q10 on Inflammation and Oxidative Stress in Chronic Kidney Disease	1000 mg ^a	6 weeks	 Metabolic Health	Randomized double-blind, placebo-controlled, crossover study in 25 chronic kidney disease (CKD) patients	- Niagen NR supplementation primarily affected gene activity related to carbohydrate/fat metabolism and immune signaling, while CoQ10 influenced genes linked to immune/stress response and fat metabolism. - Both Niagen NR and CoQ10 reduced plasma oxidative stress markers, but their effects on inflammation markers differed. NR showed mixed results, whereas CoQ10 consistently reduced inflammation. - Only Niagen NR improved mitochondrial function in monocytes.
Wu et al., 2025 Cognitive and Alzheimer's Disease Biomarker Effects of Oral Nicotinamide Riboside (NR) Supplementation in Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment	1000 mg	8 weeks	 Neurological Health	Randomized, double-blind, placebo-controlled, crossover study in 46 older adults with subjective cognitive decline and mild cognitive impairment (MCI)	- NR supplementation had no impact on cognition. - NR resulted in a 7% reduction in plasma pTau217 concentrations, a biomarker for Alzheimer's disease (AD), while placebo resulted in an 18% increase.
Yulug et al., 2025 Multi-Omics Characterization of Improved Cognitive Functions in Parkinson's Disease Patients After The Combined Metabolic Activator Treatment: A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial	2000 mg ^b	12 weeks	 Neurological Health	Randomized, double-blind, placebo-controlled, phase II study in 48 Parkinson's disease (PD) patients	- CMA supplementation did not improve motor function in PD patients. - CMA significantly improved cognitive function, particularly in patients with low baseline MoCA scores, indicative of worsened cognitive function. However, the variability in baseline MoCA scores likely influenced the observed outcomes.

^a Patients were given NR (1000 mg/day) or CoQ10 (1200 mg/day).

^b One dose of 12.35g L-serine, 1g NR, 2.55g N-acetyl-L-cysteine, and 3.73g L-carnitine tartrate for the first 28 days and two doses for the next 56 days.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Bhandari et al., 2024 Feasibility of Telehealth Exercise and Nicotinamide Riboside Supplementation in Survivors of Childhood Cancer at Risk for Diabetes: A Pilot Randomized Controlled Trial	1000 mg	6 weeks	 Muscle Health  Metabolic Health	Randomized, double-blind, placebo-controlled, pilot study in 20 childhood cancer survivors with prediabetes	- As a feasibility study, the target of achieving ≥70% compliance with both the exercise and NR interventions was successfully met, indicating that this approach was well-received by the patient population. - Niagen NR supplementation showed no significant effects on markers of glucose metabolism, body composition, or muscle strength.
Nanga et al., 2024† Acute Nicotinamide Riboside Supplementation Increases Human Cerebral NAD+ Levels In Vivo	900 mg	4 hours	 Neurological Health	Open-label, pilot study in 10 healthy subjects	Niagen NR supplementation significantly increased brain NAD+ levels by about 16% compared to baseline.
McDermott et al., 2024 Nicotinamide Riboside for Peripheral Artery Disease: The NICE Randomized Clinical Trial	1000 mg ^c	6 months	 Aging  Cardiovascular Health	Randomized, double-blind, placebo-controlled, phase II study in 90 peripheral artery disease (PAD) patients	- Niagen NR supplementation significantly improved treadmill walking time and the six-minute walking distance (by 17.6 meters), a clinically meaningful change. - Niagen NR effectively improved walking performance in individuals with PAD, while resveratrol did not enhance the benefits of NR. - Niagen NR combined with resveratrol did not significantly improve the six-minute walk distance compared to placebo.
Wu et al., 2024 Nicotinamide Riboside Augments Human Macrophage Migration via SIRT3-Mediated Prostaglandin E2 Signaling <i>Serum samples were obtained from the same group of healthy participants in both Wu et al. 2022 and Han et al. 2023.</i>	1000 mg	1 week	 Immune Health	Ex Vivo: Monocytes were extracted from young, healthy subjects and then treated with NR In Vivo: Randomized, double-blind, placebo-controlled, pilot study in 36 young, healthy subjects	Ex Vivo: - Niagen NR treatment increased levels of NAD+ and prostaglandin E2 (PGE2), a key regulator of inflammatory and immune responses, in monocytes from healthy subjects. In Vivo: - Niagen NR supplementation increased PGE2 levels in human serum.

^c Patients were given NR (1000 mg/day) alone or in combination with Resveratrol (125 mg/day).

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Berven et al., 2023[†] NR-SAFE: A Randomized, Double-Blind Safety Trial of High Dose Nicotinamide Riboside in Parkinson's	3000 mg	4 weeks	 Pharmacokinetic /Safety  Neurological Health	Randomized, double-blind, placebo-controlled, phase I study in 20 idiopathic PD patients	- High-dose Niagen NR supplementation was safe and well-tolerated with no related adverse events. - Niagen NR did not alter whole blood homocysteine, or other major methyl donor groups, suggesting no impact on methyl donor group pool. - Niagen NR significantly improved clinical symptoms of PD, suggesting augmenting NAD⁺ levels may have a symptomatic anti-Parkinson effect.
Orr et al., 2023[†] A Randomized Placebo-Controlled Trial of Nicotinamide Riboside in Older Adults with Mild Cognitive Impairment	1000 mg	10 weeks	 Neurological Health	Randomized, double-blind, placebo-controlled, phase II, pilot study in 20 primarily Hispanic older adults with MCI	- Cognitive function measures remained stable in both Niagen NR and placebo groups throughout the study. - Global methylation analyses trended towards a modest Niagen NR-associated increase in DNA methylation.
Presterud et al., 2023[†] Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia	500 mg	2 years	 Neurological Health	Open-label, single arm, observational intervention study in 10 patients with Ataxia Telangiectasia (AT)	- Long-term Niagen NR supplementation was safe and well tolerated, with no serious adverse events. - Compared to historical controls, Niagen NR supplementation significantly improved motor coordination and eye movements in AT patients. - This is the second clinical Niagen NR trial including children under the age of 18 and the longest Niagen NR supplementation study to date.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Han et al., 2023 Boosting NAD Preferentially Blunts Th17 Inflammation via Arginine Biosynthesis and Redox Control in Healthy and Psoriasis Subjects	1000 mg	1 week	 Immune Health	Ex Vivo: CD4+ T cells were extracted from 12 mild-moderate psoriasis patients and healthy subjects and then treated with NR In Vivo: Randomized, double-blind, placebo-controlled, pilot study in 25 young, healthy subjects	Ex Vivo: - NAD+/NADH ratio was reduced in psoriatic T cells compared to cells from healthy subjects. - Niagen NR treatment reduced immune responsiveness in CD4+ T cells from healthy subjects and psoriasis patients. In Vivo: - Niagen NR supplementation replicated the immune-modulating effects observed with ex-vivo Niagen NR administration, resulting in a decrease in inflammatory markers while enhancing antioxidant gene expression in immune cells.
Ahmadi et al., 2023 Randomized Crossover Clinical Trial of Coenzyme Q10 and Nicotinamide Riboside in Chronic Kidney Disease	1000 mg ^d	6 weeks	 Metabolic Health	Randomized double-blind, placebo-controlled, crossover study in 25 CKD patients	- Niagen NR supplementation showed a trend towards improved energy metabolism and submaximal exercise efficiency, suggesting better carbohydrate utilization for energy. - Niagen NR decreased plasma levels of NAD-dependent citric acid cycle intermediates, suggesting improved mitochondrial metabolism. - Niagen NR reduced short and medium-chained plasma triglycerides with a high degree of saturation (tightly packed), suggesting favorable changes in lipid metabolism. - CoQ10 reduced certain types of triglycerides and increased plasma free fatty acids.
Peluso et al., 2023 Oral Supplementation of Nicotinamide Riboside Alters Intestinal Microbial Composition in Rats and Mice, But Not Humans <i>This is the fourth publication from the Dollerup et al., 2018 group.</i>	2000 mg	12 weeks	 Gut Health	Randomized, double-blind, placebo-controlled, parallel assignment study in 40 healthy, obese sedentary men	NR supplementation did not affect the diversity or abundance of gut bacteria in humans. However, NR increased (albeit not significantly) the ratio of <i>Firmicutes</i> and <i>Proteobacteria</i>, suggesting a potential positive effect.

^d Patients were given NR (1000 mg/day) or CoQ10 (1200 mg/day).

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Gaare et al., 2023 <u>Nicotinamide Riboside Supplementation is Not Associated with Altered Methylation Homeostasis in Parkinson's Disease</u>	1000 mg	30 days	 Neurological Health	Randomized, double-blind, placebo-controlled, phase I study in 29 newly diagnosed PD patients	- NR supplementation had no impact on DNA methylation in PD patients, including in those with common mutations in the MTHFR gene. - NR also resulted in minor changes in the activity of metabolic pathways and patterns of DNA methylation. However, these changes were not harmful and did not disrupt normal DNA methylation.
Yulug et al., 2023 <u>Combined Metabolic Activators Improve Cognitive Functions in Alzheimer's Disease Patients: A Randomized, Double-Blinded, Placebo-Controlled Phase-II Trial</u>	2000 mg ^e	8 weeks	 Neurological Health	Randomized, double-blind, placebo-controlled, phase II study in 69 AD patients	- CMA supplementation improved cognitive function by 29% in AD patients. Patients with high ADAS-Cog scores (worsened cognitive function) showed improvement with CMA supplementation. - CMA also improved serum markers related to AD, as well as markers of liver and kidney health in AD patients, as seen through significant decreases in levels of ALT and uric acid.
Lapatto et al., 2023[†] <u>Nicotinamide Riboside Improves Muscle Mitochondrial Biogenesis, Satellite Cell Differentiation, and Gut Microbiota in a Twin Study</u>	1000 mg	5 months	 Muscle Health  Gut Health	Nonrandomized, open-label, parallel-assignment study in 20 BMI-discordant (one leaner, one heavier) identical twin pairs	- In the BMI-discordant twin pairs, Niagen NR supplementation was well-tolerated and increased whole blood NAD⁺ levels. - Niagen NR also increased muscle mitochondrial biogenesis and improved gut microbiota composition, as seen through an increase in the abundance of <i>Faecalibacterium prausnitzii</i>—one of the most beneficial bacteria found in the microbiome of healthy humans.
Vreones et al., 2022[†] <u>Oral Nicotinamide Riboside Raises NAD⁺ and Lowers Biomarkers of Neurodegenerative Pathology in Plasma Extracellular Vesicles Enriched for Neuronal Origin</u>	1000 mg	6 weeks	 Neurological Health	Randomized, double-blind, placebo-controlled, crossover study in 22 healthy, middle-aged, and older men and women	- Niagen NR supplementation significantly increased NAD⁺ in plasma derived human neuronal extracellular vesicles (NEVs), suggesting an increase in neuronal NAD⁺ levels. - In NEVs, Niagen NR also decreased levels of Aβ₄₂, an Alzheimer's disease biomarker, as well as biomarkers pJNK and pERK1/2, which are involved in insulin resistance and neuroinflammatory pathways.

^e One dose of 12.35g L-serine, 1g NR, 2.55g N-acetyl-L-cysteine, and 3.73g L-carnitine tartrate for the first 28 days and two doses for the next 56 days.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Wang et al., 2022† Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction	2000 mg	12 weeks	 Cardiovascular Health	Randomized, double-blind, placebo-controlled study in 30 patients with Stage C heart failure with reduced ejection fraction (HFrEF)	- High-dose Niagen NR supplementation was safe and well-tolerated, significantly, and dose-dependently (nearly) doubled whole blood NAD+ levels, and increased peripheral blood mononuclear cells (PBMCs) mitochondrial respiration. - Niagen NR also decreased expression of inflammatory markers, such as NLRP3.
Brakedal et al., 2022† The NADPARK Study: A Randomized Phase I Trial of Nicotinamide Riboside Supplementation in Parkinson's Disease	1000 mg	30 days	 Neurological Health	Randomized, double-blind, placebo-controlled, phase I study in 30 PD patients	- Niagen NR supplementation significantly increased cerebral NAD+ levels, altered brain metabolic pattern, and decreased levels of inflammatory cytokines in the cerebrospinal fluid of PD patients. - Moreover, patients experienced a mild but significant clinical improvement, and this correlated with the change in the brain's metabolic pattern.
Wu et al., 2022† Boosting NAD+ Blunts Toll-Like Receptor-4 Induced Type-I Interferon in Control and Systemic Lupus Erythematosus Monocytes	1000 mg	1 week	 Immune Health	Ex Vivo: Monocytes were extracted from young, healthy subjects and patients with systemic lupus erythematosus (SLE) and then treated with NR In Vivo: Randomized, double-blind, placebo-controlled, pilot study in 35 young, healthy subjects	Ex Vivo: - Niagen NR reduced cytokine expression and type-I interferon (IFN) signaling (which plays an important role in the human immune response) in monocytes from healthy subjects and SLE patients. In Vivo: - Niagen NR supplementation increased whole blood NAD+ levels, as well as levels of related NAD+ metabolites. - Niagen NR supplementation also replicated the effects observed with ex-vivo Niagen NR administration, resulting in a similar reduction in type-I IFN signaling in the young, healthy subjects.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Zeybel et al., 2021 <u>Combined Metabolic Activators Therapy Ameliorates Liver Fat in Nonalcoholic Fatty Liver Disease Patients</u>	2000 mg ^f	10 weeks	 Liver Health	Randomized, single-blind, placebo-controlled, phase II study in 31 patients with nonalcoholic fatty liver disease (NAFLD)	- CMA significantly decreased liver fat by 10%, and improved liver function, as seen through the significant reductions in serum alanine aminotransferase, ALT (39%), aspartate transferase, AST (30%), and uric acid (12%) levels. - CMA reduced plasma levels of inflammatory proteins, suggesting a decrease in liver inflammation. - Fecal and salivary sample analyses showed that CMA supplementation caused beneficial changes in the microbiome.
Veenhuis et al., 2021 <u>Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia</u> <i>This is the second publication from the Tinnevelt et al., 2020 group.</i>	25 mg/kg	4 months	 Neurological Health	Open-label proof-of-concept study in 24 patients with AT	- Niagen NR supplementation improved ataxia scores (SARA and ICARS). However, this improvement disappeared after NR withdrawal, indicating a temporary, symptomatic effect of Niagen NR in AT. - Niagen NR also markedly increased serum immunoglobulin G (IgG) in immunodeficient patients. - This is the first clinical study to investigate the effects of Niagen NR in patients with AT, and most notably, the first clinical Niagen NR trial in children under the age of 18.
Stocks et al., 2021[†] <u>Nicotinamide Riboside Supplementation Does Not Alter Whole-Body or Skeletal Muscle Metabolic Responses to a Single Bout of Endurance Exercise</u>	1000 mg	1 week	 Muscle Health	Randomized, double-blind, placebo-controlled, crossover study in 8 young, healthy, recreationally active men	- Niagen NR did not alter NAD-sensitive signaling pathways in skeletal muscle and did not have any effect on skeletal muscle mitochondrial respiration nor whole-body metabolism. - Although Niagen NR did not increase skeletal muscle NAD⁺ levels, it increased markers of NAD flux, demonstrating the skeletal muscle bioavailability of Niagen NR supplementation.

^f One dose of 3.73g L-carnitine tartrate, 1g NR, 12.35g serine, and 2.55g N-acetyl-L-cysteine for the first 14 days and two doses for the next 56 days.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Altay et al., 2021 Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19	2000 mg ^g	2 weeks	 Immune Health	Phase II: Randomized, open-label, placebo-controlled study in 93 patients & Phase III: Randomized, double-blind, placebo-controlled study in 309 COVID-19 patients	- After 14 days, CMA supplementation significantly reduced recovery time compared to placebo group in phase II (6.6 vs 9.3 days, respectively), as well as in phase III (5.7 vs. 9.2 days, respectively). - CMA supplementation also improved liver health and markers of inflammation in COVID-19 patients.
Li et al., 2021 NAD+-Boosting Therapy Alleviates Nonalcoholic Fatty Liver Disease via Stimulating a Novel Exerkine Fndc5/Irisin	1000 mg	2 weeks	 Liver Health	General screening test with 6 healthy human subjects	Niagen NR supplementation increased plasma levels of Fndc5/irisin. A similar increase in plasma Fndc5/irisin was observed after two weeks of exercise, suggesting Fndc5/irisin may be a link between NAD+ and physical exercise.
Nascimento et al., 2021 Nicotinamide Riboside Enhances In Vitro Beta-adrenergic Brown Adipose Tissue Activity in Humans	1000 mg	6 weeks	 Metabolic Health	Randomized, double-blind, placebo-controlled, crossover study in 8 healthy overweight and obese men and postmenopausal women	Niagen NR supplementation had no effect on cold-stimulated BAT activity.
Tinnevelt et al., 2020 Variable Selection in Untargeted Metabolomics and the Danger of Sparsity	25 mg/kg	4 months	 Neurological Health	Comparative study in 14 patients with ataxia-telangiectasia (AT)	Niagen NR-related pathways and metabolites significantly increased after Niagen NR supplementation.

^g "Combined metabolic activators" or "CMA," in combination with hydroxychloroquine (HCQ) or favipiravir (FP) for the treatment of patients with COVID-19. The CMA was administered twice per day for 14 days, and each dose consisted of 3.73g L-carnitine tartrate, 1g NR, 12.35g serine, and 2.55g N-acetyl-L-cysteine.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Zhou et al., 2020[†] <u>Boosting NAD Level Suppresses Inflammatory Activation of PBMCs in Heart Failure</u>	2000 mg	5–9 days	 Cardiovascular Health	Ex vivo and pilot clinical study in 5 Stage D heart failure patients	- Niagen NR supplementation increased whole blood NAD⁺ levels and mitochondrial respiration rate of the heart failure patients' PBMCs. - Niagen NR reduced the production and gene expression of proinflammatory cytokines. - The systemic inflammation in heart failure patients was causally linked to mitochondrial function of the PBMCs.
Zhang et al., 2020 <u>The Acute Effect of Metabolic Cofactor Supplementation: A Potential Therapeutic Strategy Against Non-Alcoholic Fatty Liver Disease</u>	1000 mg ^h	5 days	 Liver Health	Acute, single dose, 5-day pilot clinical study in 19 healthy, male subjects	- CMA supplementation significantly decreased blood plasma levels of markers associated with increased liver fat, as well as blood plasma levels of branch chain amino acids. - Mathematical modeling results showed a global increase in fat metabolism, decreased glucose metabolism, and increased synthesis of NAD⁺, carnitine, and glutathione.
Remie et al., 2020[†] <u>Nicotinamide Riboside Supplementation Alters Body Composition and Skeletal Muscle Acetylcarnitine Concentrations in Healthy Obese Humans</u>	1000 mg	6 weeks	 Muscle Health  Metabolic Health	Randomized, double-blind, placebo-controlled, crossover study in 15 healthy, overweight, or obese, sedentary men and women	- Niagen NR significantly increased markers of enhanced NAD⁺ metabolism in human skeletal muscle (e.g., NAAD and MeNam). - Minor beneficial changes in body composition, sleeping metabolic rate, and skeletal muscle acetyl-carnitine concentrations were found.
Dollerup et al., 2019 <u>Nicotinamide Riboside Does Not Alter Mitochondrial Respiration, Content or Morphology in Skeletal Muscle from Obese and Insulin-Resistant Men</u> <i>This is the third publication from the Dollerup et al., 2018 group.</i>	2000 mg	12 weeks	 Muscle Health  Metabolic Health	Randomized, double-blind, placebo-controlled, parallel assignment study in 40 healthy, obese sedentary men	- Protein levels of nicotinamide phosphoribosyltransferase (NAMPT), an essential NAD⁺ biosynthetic enzyme in skeletal muscle, decreased by 14% with Niagen NR. However, Niagen NR supplementation did not affect NAD⁺ metabolite concentrations in skeletal muscle. - Respiration, distribution, and quantity of muscle mitochondria were also unaffected by Niagen NR.

^h A combination supplement consisting of 1g NR, 20g L-serine, 5g N-acetyl-L-cysteine, and 3g L-carnitine.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Elhassan et al., 2019† <u>Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures</u>	1000 mg	3 weeks	 Muscle Health	Randomized, double-blind, placebo-controlled, crossover study in 12 marginally overweight, but otherwise healthy aged men	- Niagen NR supplementation increased the muscle NAD+ metabolome - Niagen NR significantly decreased levels of circulating inflammatory markers (IL-6, IL-5, and IL-2, and TNF-α, compared to baseline).
Dollerup et al., 2019 <u>Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men with Obesity</u> <i>This is the second publication from the Dollerup et al., 2018 group.</i>	2000 mg	12 weeks	 Metabolic Health	Randomized, double-blind, placebo-controlled, parallel assignment study in 40 healthy, obese sedentary men	- Niagen NR supplementation did not affect fasting or post-glucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP. - β-cell function did not respond to Niagen NR intervention and no changes in circulating adiponin or bile acids were observed.
Conze et al., 2019† <u>Safety and Metabolism of Long-Term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Healthy Overweight Adults</u>	100 mg 300 mg 1000 mg	8 weeks	 Pharmacokinetic/ Safety	Randomized, double-blind, placebo-controlled, parallel assignment study in 140 overweight, but otherwise healthy men and women	Niagen NR supplementation significantly and dose-dependently increased whole blood NAD+ levels by 22%, 51%, and 142%, respectively, within two weeks. These levels were maintained throughout the remainder of the study.
Dollerup et al., 2018† <u>A Randomized Placebo-Controlled Clinical Trial of Nicotinamide Riboside in Obese Men: Safety, Insulin-Sensitivity, and Lipid-Mobilizing Effects</u>	2000 mg	12 weeks	 Pharmacokinetic /Safety  Liver Health  Metabolic Health	Randomized, double-blind, placebo-controlled, parallel assignment study in 40 healthy, obese sedentary men	- Niagen NR-supplemented subjects had an average 2% absolute reduction in liver fat content compared to a 0.2% absolute reduction in the placebo group. - Of the subset of men who started the trial with greater than 5% liver fat, 69% experienced a reduction in liver fat compared to only 39% of the men taking the placebo. - Niagen NR supplementation tended to decrease circulating levels of ALT in the blood.

Publication	Dose	Duration	Health Area	Study Design	Key Outcomes
Martens et al., 2018[†] <u>Chronic Nicotinamide Riboside Supplementation is Well-Tolerated and Elevates NAD⁺ in Healthy Middle-Aged and Older Adults</u>	1000 mg	6 weeks	 Pharmacokinetic/ Safety  Cardiovascular Health	Randomized, double-blind, placebo-controlled, crossover study in 30 healthy, middle-aged, and older men and women	- Niagen NR supplementation significantly increased average NAD⁺ levels by 60% compared to placebo. - Niagen NR tended to lower blood pressure, especially in subjects with elevated blood pressure (in the stage I hypertension range). - Niagen NR also tended to decrease aortic stiffness.
Airhart et al., 2017[†] <u>An Open-Label, Non-Randomized Study of the Pharmacokinetics of the Nutritional Supplement Nicotinamide Riboside (NR) and Its Effects on Blood NAD⁺ Levels in Healthy Volunteers</u>	2000 mg	9 days	 Pharmacokinetic/ Safety	Non-randomized, open-label study in 8 healthy men and women	- Niagen NR supplementation significantly increased blood NAD⁺ concentrations between baseline and Day 9. On average, NAD⁺ levels increased 2-fold. - No significant changes were observed in blood pressure, body temperature, body weight, white blood cell count, lactate dehydrogenase (LDH), or AST.
Trammell et al., 2016[†] <u>Nicotinamide Riboside is Uniquely and Orally Bioavailable in Mice and Humans</u>	100 mg	24 hours	 Pharmacokinetic /Safety	Randomized, double-blind, single dose, three-arm study in 12 healthy men and women	- Single oral doses of Niagen NR significantly and dose-dependently increased NAD⁺ and related metabolites in PBMCs. - Mouse pharmacokinetic data demonstrated that Niagen NR increased NAD⁺ levels better than niacin (NA) and stimulated NAD⁺ consuming activities in the liver more than nicotinamide (NAM).
	300 mg				
	1000 mg				

Clinical Research on Niagen®



Niagen. BIOSCIENCE